A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Minghui’s MHB088C will soon start phase 3 in China.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
